These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

73 related articles for article (PubMed ID: 10623385)

  • 1. Discovering why HIV drugs fail.
    Check W
    CAP Today; 1999 Oct; 13(10):1, 12-6, 20 passim. PubMed ID: 10623385
    [No Abstract]   [Full Text] [Related]  

  • 2. Highly active antiretroviral therapy failure and protease and reverse transcriptase human immunodeficiency virus type 1 gene mutations.
    Monno L; Appice A; Cavaliere R; Scarabaggio T; Angarano G
    J Infect Dis; 1999 Aug; 180(2):568-71. PubMed ID: 10395885
    [No Abstract]   [Full Text] [Related]  

  • 3. Anti-HIV therapies early in the pipeline.
    Bartnof HS
    BETA; 1999; 12(4):57. PubMed ID: 11367256
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antiviral treatment of HIV infection.
    Thomas MG; Ellis-Pegler RB
    N Z Med J; 1998 Sep; 111(1074):353-4. PubMed ID: 11039818
    [No Abstract]   [Full Text] [Related]  

  • 5. Multiclass primary antiretroviral drug resistance in a patient presenting HIV-1/2 dual infection.
    Castro E; Recordon-Pinson P; Cavassini M; Fleury H
    Antivir Ther; 2012; 17(3):593-4. PubMed ID: 22301389
    [No Abstract]   [Full Text] [Related]  

  • 6. Genotype and antiretroviral drug resistance of human immunodeficiency virus-1 in Saudi Arabia.
    Jamjoom GA; Azhar EI; Madani TA; Hindawi SI; Bakhsh HA; Damanhouri GA
    Saudi Med J; 2010 Sep; 31(9):987-92. PubMed ID: 20844809
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical implications of resistance to antiretroviral drugs.
    Vella S
    AIDS Clin Care; 1997 Jun; 9(6):45-7, 49, 52. PubMed ID: 11364354
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Epidemiology of genotypic resistance of HIV-1 in Valencia. A 4-year study].
    Molina JM; Córdoba J; Gil A; Gobernado M
    Rev Esp Quimioter; 2007 Sep; 20(3):346-53. PubMed ID: 18080033
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Advances in novel anti-HIV-1 drugs and drug candidates: 2005-2008].
    Zheng PR; Xue H; Xiao ZY; Liu G
    Yao Xue Xue Bao; 2010 Feb; 45(2):154-64. PubMed ID: 21351426
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Oligonucleotide ligation assay for detection of mutations associated with reverse transcriptase and protease inhibitor resistance in non-B subtypes and recombinant forms of human immunodeficiency virus type 1.
    Vega Y; Pérez-Alvárez L; Delgado E; Muñoz M; Casado G; Carmona R; Sierra M; Vázquez de Parga E; Pinilla M; García V; Medrano L; Contreras G; Thomson M; Nájera R
    J Clin Microbiol; 2005 Oct; 43(10):5301-4. PubMed ID: 16208003
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antiretroviral resistance patterns and factors associated with resistance in adult patients failing NNRTI-based regimens in the Western Cape, South Africa.
    van Zyl GU; van der Merwe L; Claassen M; Zeier M; Preiser W
    J Med Virol; 2011 Oct; 83(10):1764-9. PubMed ID: 21837793
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The nucleoside reverse transcriptase inhibitors, nonnucleoside reverse transcriptase inhibitors, and protease inhibitors in the treatment of HIV infections (AIDS).
    De Clercq E
    Adv Pharmacol; 2013; 67():317-58. PubMed ID: 23886005
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Profile of drug resistance mutations among HIV-1-infected Tunisian subjects failing antiretroviral therapy.
    Jlizi A; Ben Ammar El Gaaied A; Slim A; Tebourski F; Ben Mamou M; Ben Chaabane T; Letaief-Omezzine A; Chakroun M; Garbouj M; Ben Rejeb S
    Arch Virol; 2008; 153(6):1103-8. PubMed ID: 18483694
    [TBL] [Abstract][Full Text] [Related]  

  • 14. New antiretroviral agents.
    Gallant JE
    Hopkins HIV Rep; 1999 Mar; 11(2):3, 12. PubMed ID: 11366248
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Basic approaches to anti-HIV resistance].
    Baba M
    Nihon Rinsho; 2002 Apr; 60(4):763-8. PubMed ID: 11968785
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Genotypic resistance and the treatment of HIV-1 infection in Espírito Santo, Brazil.
    Pilcher CD; Perkins MD; Fiscus SA; Johnston DM; Dietze R; Duque UH; Zago AM; Assad-Antunes F; Eron JJ
    J Infect Dis; 1999 May; 179(5):1259-63. PubMed ID: 10191233
    [TBL] [Abstract][Full Text] [Related]  

  • 17. High prevalence of antiretroviral drug resistance among HIV-1-untreated patients in Guinea-Conakry and in Niger.
    Charpentier C; Bellecave P; Cisse M; Mamadou S; Diakite M; Peytavin G; Tchiombiano S; Teisseire P; Pizarro L; Storto A; Brun-Vézinet F; Katlama C; Calvez V; Marcelin AG; Masquelier B; Descamps D
    Antivir Ther; 2011; 16(3):429-33. PubMed ID: 21555827
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antiretroviral pharmacology issues and management.
    Piscitelli SC
    BETA; 1999; 12(4):9-15. PubMed ID: 11367266
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Natural residues versus antiretroviral drug-selected mutations in HIV type 1 group O reverse transcriptase and protease related to virological drug failure in vivo.
    de Baar MP; Janssens W; de Ronde A; Fransen K; Colebunders R; Kestens L; van der Groen G; Goudsmit J
    AIDS Res Hum Retroviruses; 2000 Sep; 16(14):1385-94. PubMed ID: 11018858
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Anti-HIV drugs].
    Raffi F
    Rev Prat; 1999 Oct; 49(16):1763-71. PubMed ID: 10578607
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.